Dr Cate Lockhart Discusses Deciding Between Trastuzumab Biosimilars

There are a number of trastuzumab biosimilars available, but so far there have not been any patient characteristics that have played a role in which ones are prescribed, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium.

There are a number of trastuzumab biosimilars available, but so far there have not been any patient characteristics that have played a role in which ones are prescribed, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium.

Transcript

How does patient characterization play a role in the use of trastuzumab biosimilars?

You know, so far, no. In our preliminary analysis, we haven't seen any real differences in patient populations who are treated with one or another. It's possible that there are some regional differences. We don't tend to tease that out. Our population in the databases that we work with are fairly broadly distributed around the United States. And we're also looking at commercially insured population. So, there's some limitations for our particular data set.

But in terms of the basic patient characteristics, we haven't really seen anything notably different across them.